The company partnered with the government of Barbados to advance kidney disease therapy
Research instituted BioMed X has launched a new research project, partnering with the government of Barbados to advance therapy for early diabetic kidney disease.
“By partnering directly with the government of Barbados and with support from the European Union, we are applying our global talent-sourcing and incubation model to a real-world public health challenge in an underrepresented population,” said BioMex X Barbados CEO Leisel Juman.
“This initiative creates a structured pathway from fundamental discovery to real-world impact – while equipping Barbados with the capabilities to contribute meaningfully to the global innovation landscape.”
The project is supported by the EU’s PharmaNext programme, which aims to modernise the regulatory framework for medicines, encourage innovation, enhance access and address shortages.
“Through the PharmaNext Programme, the European Union is committed to supporting innovative research partnerships that address global health challenges while strengthening scientific capacity,” said EU Ambassador to Barbados H.E. Fiona Ramsey. “This project exemplifies how European support, local leadership, and international scientific excellence can come together to deliver impactful, inclusive innovation.”
BioMed X and its partners are seeking interdisciplinary research proposals that focus on the following:
-
Focused molecular profiling of Barbadian Type 2 Diabetes patients with early diabetic kidney disease and matched healthy controls.
-
Development of an AI-driven digital African twin model capturing population-specific molecular heterogeneity, disease trajectories, and predictive stratification features.
-
Identification and validation of novel molecular biomarkers to inform personalised diabetic kidney disease risk assessment and treatment adaptation in Barbados.
The objective of the project is to address the biological heterogeneity of early diabetic kidney disease in the Barbadian population. Researchers wish to understand the molecular mechanisms driving early diabetic kidney disease in individuals with Type 2 Diabetes in Barbados through deep molecular profiling and AI-based modelling.
By combining multi-layered molecular characterisation of Barbadian patients and healthy controls with AI-driven modelling, the project intends to construct a population-specific digital African twin. This model should enable refined patient stratification, improved biomarker discovery and adaptive, data-driven therapeutic strategies.
“This launch reflects our commitment to positioning science and technology at the heart of Barbados’ future,” said Jonathen Reid, minister of innovation, industry, science and technology. “Through collaboration, talent development, and early engagement of our young people, we are laying the groundwork for an innovation ecosystem that is globally connected and capable of driving sustainable national growth.”